At IFM Therapeutics, LLC, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response.
The majority of advances in immunotherapy have focused largely on targeting the adaptive immune system, which historically has been the best-characterized part of the immune system. While many of these approaches can work well, the benefit is seen only in a small number of diseases and over time, patients can lose response to these therapies. However, our understanding of the innate immune system has matured sufficiently, that we can now think about exploiting this biology to advance a new generation of medicines for inflammatory disorders and cancer. IFM Therapeutics, LLC has brought together the key academic thought leaders and advisors in this field, along with an exceptionally talented group of pharmaceutical scientists and executives, to make this goal a reality.
IFM Therapeutics, LLC was formed following the acquisition of IFM Therapeutics by Bristol-Myers Squibb in 2017. IFM Therapeutics, LLC retained its personnel and facilities, as well as its remaining research programs focused on curbing immune responses that lead to inflammatory diseases and fibrosis.
By focusing on innate immunity, IFM Therapeutics, LLC is looking to solve the limitations faced by current immunotherapies by dramatically increasing the number of patients that benefit from treatment and extending the duration of therapeutic response.